- Home
- CAST vs TLPH Comparison
CAST vs TLPH Comparison
Compare CAST & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAST | TLPH |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 54.5M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CAST | TLPH |
|---|---|---|
| Price | $1.07 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.13 |
| AVG Volume (30 Days) | ★ 240.9K | 77.5K |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $710,882.00 | ★ $2,151,000.00 |
| Revenue This Year | $323.40 | N/A |
| Revenue Next Year | $1,478.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 13.17 | N/A |
| 52 Week Low | $0.50 | $0.69 |
| 52 Week High | $12.20 | $1.57 |
Technical Indicators
Market Signals| Indicator | CAST | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 24.05 |
| Support Level | $0.89 | $0.74 |
| Resistance Level | $1.49 | $0.89 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 8.11 | 6.88 |
Price Performance
Historical ComparisonAbout CAST FreeCast Inc. Class A Common Stock
FreeCast Inc is a streaming technology company that provides platform-as-a-service solutions for television and digital video distribution. Its platform infrastructure supports telecom operators, internet service providers, broadcasters, municipalities, utilities, brands, and device manufacturers in deploying and managing digital media and other streaming services.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.